Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lawrence Owusu

Physician Assistant, Medical Oceanside, CA Physician Assistant

NPI 1720185614 CMS profile 10724349

3998 Vista Way, Oceanside, CA 92056

Open in the dashboard

General payments

$7,968

256 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Owusu of Oceanside, CA is reported in the CMS Open Payments database as having received $7,968 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,107 77
2024 General $2,037 88
2023 General $1,409 71
2022 General $260 12
2021 General $154 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Owusu
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lawrence Owusu were reported at $4,107. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lawrence Owusu Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $154 $156 $41–$563 $132
2022 $260 $185 $55–$649 $149
2023 $1,409 $199 $58–$717 $160
2024 $2,037 $206 $62–$740 $164
2025 $4,107 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $3,155 34 payments
  2. Abbott Laboratories $865 49 payments
  3. Boston Scientific Corporation $537 23 payments
  4. Collegium Pharmaceutical, Inc. $407 24 payments
  5. Nalu Medical, Inc. $331 23 payments
  6. Painteq LLC $267 8 payments
  7. Curonix LLC $242 13 payments
  8. Vertex Pharmaceuticals Incorporated $240 9 payments
  9. TerSera Therapeutics LLC $231 8 payments
  10. Virtus Pharmaceuticals LLC $229 10 payments
  11. Other $1,464 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,294 255 payments
  2. Travel and Lodging $1,674 1 payment
Products named General payments · program years 2021–2025
  1. Evoke $3,155 34 payments
  2. BELBUCA $350 21 payments
  3. PROCLAIM $340 16 payments
  4. Nalu Neurostimulation System $331 23 payments
  5. OCTRODE $276 19 payments
  6. PAINTEQ $267 8 payments
  7. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $242 13 payments
  8. Prialt $231 8 payments
  9. LEVORPHANOL TARTRATE $229 10 payments
  10. ReActiv8 $199 3 payments
  11. Other $1,870 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,357

Median for Physician Assistant: 241

Drug cost

$301,090

Median for Physician Assistant: $4,110

Branded share of claims

42.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 125 $96,213
Xtampza Er Oxycodone Myristate Brand 89 $48,311
Nucynta Er Tapentadol Hcl Brand 12 $20,772
Oxycontin Oxycodone Hcl Brand 37 $16,304
Nucynta Tapentadol Hcl Brand 15 $15,969
Buprenorphine Generic 45 $12,991
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 399 $12,781
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 481 $11,858
Fentanyl Generic 74 $7,367
Hysingla Er Hydrocodone Bitartrate Brand 11 $5,760

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$91,861

Of which drugs: $2,916

Medicare patients

193

Average age 72

Services billed

1,638

109 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 34%
Diabetes 31%
Ischemic heart disease 27%
Chronic kidney disease 23%
Heart failure 21%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 87 $47
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 44 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $155
$155 125 —
Prialt
  • TerSera Therapeutics LLC $92
$92 — —
LEVORPHANOL TARTRATE
  • Virtus Pharmaceuticals LLC $60
$60 — —
Qutenza
  • Averitas Pharma Inc. $25
$25 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $21
$21 89 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record